SUPPLY OF ANTIHYPERTEN SIVE DRUG S AND CARDIOVA SCULAR MORTALITY IN POLAND IN 2000–2010
Background and objective. In Poland, the sale of antihypertensive drugs has significantly increased since 2000. According to that fact, the aim of our study was to determine if the increased use of antihypertensive drugs correlates with the decreasing mortality due to cardiovascular diseases (CVD) including hypertension (HT).
Methods. The analysis is based on data on annual national sales (million units) of four types of antihypertensive drugs in 2000–2010. For the same period standardized mortality rates were calculated based on the data available from the Central Statistical Office in Poland. Data analysis involved correlation analysis between annual mortality rates due CVD and HT and country-wide annual sales of antihypertensive drugs (2000–2010).
Results. In the period 2000–2010, standardized mortality rates of CVD in the whole population followed a decreasing trend. Analysis of correlation of CVD with specific drug provided the following findings: diuretics (r=-0.97; p<0.0001) beta-blockers (r=-1.0; p<0.0001) renin-angiotensin system (RAS) inhibitors (r=-0.72 p=0.01) calcium-channel blockers (r=-0.82; p=0.001) Standardized mortality rates for the HT showed fluctuating trend. Correlations of that mortality with global sale of these drugs were no longer negative: r=0.54; p=0.08, r=0.56; p=0.08 r=0.55; p=0.07; r=0.63; p=0.03, respectively.
Conclusions. In Poland, in 2000–2010, an improved access to pharmacological control of HT was associated with an apparent reduction in mortality from CVD but not from HT. The latter findings might reflect imprecise definition of HT as a cause of death or the fact that HT leads to other cardiologic events usually reported as a cause of death.
Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011; 377: 568–577.
Barański K, Zejda JE.: Nadciśnienie tętnicze jako główna przyczyna zgonów w Polsce w latach 1990-2010. Nadciśnienie tętnicze, 2014; 18(2): 74.
Cheng A, Braunstein JB, Dennison C, Nass C, Blumenthal RS. Reducing global risk for cardiovascular disease: using lifestyle changes and pharmacotherapy. Clin Cardiol. 2002; 25(5): 205–12.
Gudmundsson LS, Johannsson M, Thorgeirsson G, Sigfusson N, Sigvaldason H, Witteman JC. Hypertension control as predictor of mortality in treated men and women, followed for up to 30 years. Cardiovasc Drugs Ther. 2005; 19(3): 227–35.
White WB.: Update on the drug treatment of hypertension in patients with cardiovascular disease. Am J Med. 2005; 118(7): 695–705.
WHO age standardization of rates: a new who standard: Ahmad OB, Boschi-Pinto C, Lopez AD, Murray C, Lozano R, Inoue M.: GPE Discussion Paper Series: No.31 EIP/GPE/EBD World Health Organization 2001.
Zatonski WA, Willett W.: Changes in dietary fat and declining coronary heart disease in Poland: population based study BMJ 2005; 331:187.
Bandosz P, O’Flaherty M, Drygas W, Koziarek J, Wyrzykowski B, Rutkowski M, et al.: Explaining the decline in coronary heart disease mortality in Poland between 1991 and 2005 ESC Congress, Stockholm, Sweden (2010 28 Aug–01 Sep) Abstract 1119.
Unal B, Critchley JA, Capewell S.: Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation, 109 (2004): 1101–1107.
Zatonski WA, McMichael AJ, Powles JW, Ecological study of reasons for sharp decline in mortality from ischaemic heart disease in Poland since 1991 BMJ. 1998 Apr 4; 316(7137): 1047–105.
Papp R, Csaszar A, Paulik E, Balogh S.: Correlations between prescription of anti-hypertensive medication and mortality due to stroke. BMC Cardiovascular Disorders 2012, 12: 1.
Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA.: Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011; 305(9): 913–22.
Ostrowski M, Zanchetti A, Nikfar S, Muntner P, Aronow WS, Howard VJ, Wong ND, Howard G, Abdollahi M, Banach M.: The effect of hypertension pharmacotherapy in older adults. The results of a meta-analysis of 11 randomized control trials with 40325 patients. European Heart Journal (2014) 35 (Abstract Supplement), 1192.
Perez MI, Musini VM, Wright JM.: Effect of early treatment with anti-hypertensive drugs on short and long-term mortality in patients with an acute cardiovascular event. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006743.
Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database of Systematic Reviews 2012, Issue 8.
Authors who sent their manuscript to International Journal of Medicine and Medical Research agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC-BY-NC that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).